ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Upadacitinib

Janus-Associated Kinase (Jak) Inhibitors

Sold as RINVOQ

GB MHRACA Health CanadaEU EMA

Drug class: Janus-Associated Kinase (Jak) Inhibitors
Availability: See label
Routes: Oral
Markets covered: 3
Products on record: 13

L04AFJanus-Associated Kinase (Jak) Inhibitors

Overview

Upadacitinib is an active pharmaceutical ingredient in the Janus-Associated Kinase (Jak) Inhibitors group (L04AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	9	May 22, 2026
CA Canada	Health Canada	3	December 31, 2025
EU European Union	EMA	1	November 28, 2025

GBUnited Kingdom· MHRA

9 products

Uses

GBOfficial regulatory label· revised May 22, 2026[1]

Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
RINVOQ may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.
RINVOQ may be used as monotherapy or in combination with methotrexate. Axial spondyloarthritis Non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti- inflammatory drugs (NSAIDs).

CACanada· Health Canada

3 products

Side effects & warnings

CAOfficial regulatory label· Adverse reactions· revised December 31, 2025[2]

). RINVOQ (upadacitinib) Page 17 of 108 Immune RINVOQ should not be used concomitantly with other potent immunosuppressants. Concomitant use of RINVOQ with other potent immunosuppressants (such as azathioprine, cyclosporine, tacrolimus), biologic DMARDs, or other JAK inhibitors has not been evaluated in clinical studies.
2 Drug Interactions Overview). Immunizations No data are available on the response to vaccination with live vaccines in patients receiving RINVOQ. Live or attenuated vaccines should not be used immediately prior to or during RINVOQ therapy.
The interval between live vaccinations and initiation of RINVOQ therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents. Prior to initiating RINVOQ treatment, it is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, in agreement with current immunization guidelines.

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised November 28, 2025[3]

Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
RINVOQ may be used as monotherapy or in combination with methotrexate. 3 Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.
RINVOQ may be used as monotherapy or in combination with methotrexate. Axial spondyloarthritis Non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti- inflammatory drugs (NSAIDs).

Drug interactions

Known interactions involving Upadacitinib. Select one for details. This list is informational and not a complete interaction checker.

Abatacept Abemaciclib Acalabrutinib Adalimumab Aflibercept Aldesleukin Alefacept Alemtuzumab Altretamine Amprenavir Anakinra Antilymphocyte Immunoglobulin Apalutamide Asparaginase Atazanavir Atezolizumab Avapritinib Axicabtagene Ciloleucel Azacitidine Azathioprine Baricitinib Basiliximab Belantamab Mafodotin Belatacept Belimumab Belinostat Bendamustine Betamethasone Bexarotene Bleomycin Blinatumomab Boceprevir Bortezomib Bosutinib Brentuximab Vedotin Brexucabtagene Autoleucel Brigatinib Brodalumab Budesonide Busulfan Cabazitaxel Canakinumab Capecitabine Carbamazepine Carboplatin Carfilzomib Carmustine Ceritinib Certolizumab Pegol Chlorambucil Cisplatin Cladribine Clarithromycin Clofarabine Clozapine Cobicistat Cobimetinib Conivaptan Copanlisib Corticotropin Cosyntropin Cyclophosphamide Cyclosporine Cytarabine Dacarbazine Dactinomycin Daratumumab Dasatinib Daunorubicin Decitabine Deferiprone Deflazacort Delavirdine Denileukin Diftitox Dexamethasone Dimethyl Fumarate Dinutuximab Diroximel Fumarate Docetaxel Doxorubicin Dupilumab Durvalumab Duvelisib Efalizumab Elotuzumab Enzalutamide Epirubicin Eribulin Etanercept Etoposide Everolimus Fingolimod Floxuridine Fludarabine Fludrocortisone Fluorouracil Fosamprenavir Fosphenytoin Gemcitabine Gemtuzumab Ozogamicin Golimumab Guselkumab Hydrocortisone Hydroxyurea Ibritumomab Tiuxetan Ibrutinib Idarubicin Idelalisib Ifosfamide Imatinib Indinavir Inebilizumab Infliximab Inotuzumab Ozogamicin Interferon Alfa-2b Interferon Alfa-N1 Interferon Alfacon-1 Interferon Gamma-1b Irinotecan Isatuximab Itraconazole Ixabepilone Ixazomib Ixekizumab Ketoconazole Leflunomide Lenalidomide Levamisole Linezolid Lisocabtagene Maraleucel Lomustine Lonafarnib Lumacaftor Lurbinectedin Mechlorethamine Melphalan Mercaptopurine Methotrexate Methylprednisolone Midostaurin Mitomycin Mitotane Mitoxantrone Mogamulizumab Monomethyl Fumarate Mycophenolate Mofetil Mycophenolic Acid Natalizumab Naxitamab Nefazodone Nelarabine Nelfinavir Nilotinib Niraparib Obinutuzumab Ocrelizumab Ofatumumab Olaparib Olaratumab Omacetaxine Mepesuccinate Osimertinib Oxaliplatin Ozanimod Paclitaxel Palbociclib Panobinostat Pazopanib Pegaspargase Peginterferon Alfa-2a Peginterferon Alfa-2b Pemetrexed Pentostatin Phenobarbital Phenytoin Plicamycin Polatuzumab Vedotin Pomalidomide Ponatinib Posaconazole Pralatrexate Prednisolone Prednisone Primaquine Primidone Procainamide Procarbazine Ribociclib Rifampin Rifapentine Rilonacept Risankizumab Ritonavir Rituximab Romidepsin Rucaparib Ruxolitinib Saquinavir Sarilumab Satralizumab Secukinumab Selinexor Siltuximab Siponimod Sirolimus Streptozocin Tacrolimus Tafasitamab Talazoparib Telaprevir Telithromycin Temozolomide Temsirolimus Teniposide Teriflunomide Thalidomide Thioguanine Thiotepa Tildrakizumab Tisagenlecleucel Tocilizumab Tofacitinib Topotecan Tositumomab Trabectedin Trastuzumab Triamcinolone Trifluridine Trimetrexate Troleandomycin Tucatinib Uracil Mustard Ustekinumab Vedolizumab Venetoclax Vinblastine Vincristine Vinorelbine Voriconazole Zanubrutinib Zidovudine

Showing 240 of 306. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PLGB410420042 · revised May 22, 2026
[2]Health Canada (DPD) · 02495155 · revised December 31, 2025
[3]European Medicines Agency · EMEA/H/C/004760 · revised November 28, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.